NFL running back Mike James joins the cannabis health and wellness company
A cannabis health and wellness company out of California has turned to the National Football League (NFL) to raise marijuana awareness. Stigma, a company that specializes in cannabis lifestyle products such as cannabidiol (CBD) performance products and activewear, has tapped NFL running back Mike James to be its brand ambassador. James is the perfect choice and is no stranger to the positive benefits of marijuana.
In 2013, James was enjoying a successful career as a running back with the Tampa Bay Buccaneers of the NFL. His career hit a major roadblock when he suddenly broke his ankle during a game and turned to opioids to combat the pain. Upon realizing how the drugs were impacting him physically and mentally, he turned to marijuana and was immediately surprised by the positive results.
This year, his petition to use cannabis as an alternative, natural painkiller to the pharmaceutical drugs that are distributed like breath mints was denied by the NFL. However, James isn’t giving up so easily. The current free agent has become a strong advocate for marijuana and travels around the world to conferences in order to share his personal cannabis experience.
James asserts, “If we want to redefine the world’s perception of cannabis, we need more positive role models to step up and share their story. We have a chance today to make a significant impact on how cannabis is viewed. We couldn’t have asked for a better representative of our brand as we embark on this journey.”
Stigma is hoping that James’ status will help the marijuana industry shed its “stoner” status. The company’s founder and CEO, Anthony Gonzales, adds, “We’re thrilled to have Mike as part of our team. He’s had the courage as a professional athlete to step out from the shadows and showcase how cannabis can be a part of a healthy lifestyle. He’s using his experience to get people, both inside and outside the NFL, to think differently about cannabis. Helping people view it as a real treatment option over opioids.”